A pharmaceutical company has offered to pay the NHS £8m following an investigation into suspected collusion.
The head of LloydsPharmacy’s parent company has hit out at government business rates.
Community pharmacy contractors in England are being told by PSNC that they need to register for the MYS application.
The head of LloydsPharmacy’s parent company criticises the doubling of rent on one of its branches.
A disorderly no deal would disrupt the UK’s chemical and pharmaceutical supply chains overnight.
Boots is trialling technology that will allow patients who cannot speak English to access its services.
LloydsPharmacy’s parent company singles out NHS “underfunding” and falling prescription numbers as challenges.
McKesson UK chief Toby Anderson said the new settlement is “neither as good as we hoped nor as bad as we feared.”
The Government has announced that it is pushing back next year's early May Bank Holiday to Friday, May 8 2020.
AMCo, Morningside and Alliance Healthcare have been accused of illegal market sharing over nitrofurantoin.
Community pharmacy has its first multi-year funding settlement, but funding is fixed at current levels of £2.592bn per year.
A patient health app is to extend its appointment booking feature to include community pharmacy services.
Pharmacy2U said it has been paid £5m less in NHS fees than community pharmacies.
The subscription-style model will pay pharmaceutical companies upfront for access to medicines.
NPA members must ascertain the contents of any CBD products they intend to sell or risk losing their indemnity.
With the signing of the agreement, the PDAU now has collective bargaining rights to negotiate on pay, hours and holiday.
Avicenna sells its entire issued share capital to the healthcare company Juno Health Ltd.
McKesson UK appoints former retail pharmacy operations director of Boots as its new chief retail officer.
DHSC warns the main risk to the supply of medicines remains the likely bottlenecks at the short straits crossings.
Average manufacturer selling prices for readily available generics are around half the Drug Tariff price, says BGMA commissioned report.